Mobile website
Clinical Research
Dendritic cell-cytokine induced killer cells combined with chemotherapy in treatment of advanced non-small cell lung cancer patients: The clinical effectiveness
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective : To evaluate the safety and therapeutic effect of dentritic cell (DC)-cytokine induced killer cells (CIKs) combined with chemotherapy in treatment of advanced non-small cell lung cancer (NSCLC) patients. Methods: Fifty patients with advanced NSCLC (stage Ⅲ to Ⅳ), who were admitted to Tumor Hospital of Shanxi Province from August 2008 to January 2010, were treated by DC-CIK combined with chemotherapy (docetaxel+cisplatin) and were taken as the combined treatment group; another fifty advanced NSCLC patients who were treated with chemotherapy alone (docetaxel+cisplatin) during the same period were taken as controls. The immune function, therapeutic effect, 1-year survival, life quality, and side effects were compared between the two groups. Furthermore, the safety and therapeutic effects of DC-CIK therapy were observed. Results: DC-CIK cells from NSCLC patients were successfully induced, the ratios of CD3+CD8+ and CD3＋CD56+ cells in DC-CIK cells were significantly increased after culture (P＜0.05). There were no obvious changes of T cell subsets in the peripheral blood after combined therapy, and the therapy increased IFN-γ level (P<0.05). In the chemotherapy group, the ratios of CD3+CD4+, CD3+CD8+, CD3-CD56+ cells and IL-2, TNF-α levels were significantly decreased after cell culture (P＜0.05); and the ratios of CD3+CD8+, CD3+CD56+ cells in DC-CIK was increased (P＜0.05). The disease control rate (DCR) of combined therapy group was higher than that in chemotherapy group (78.0% vs 56.0%, P<0.05); the 1-year survival rates of combined therapy group and chemotherapy group were 50% and 44%, respectively, showing no significant difference (P>0.05). The combined therapy group had less side effects（including bone marrow suppression, nausea and vomiting, and peripheral nerve toxicity）compared with the control chemotherapy group (P＜0.05). The physical condition and appetite of NSCLC patients in the combined therapy group were better than those in chemotherapy group.Conclusion: Treatment with DC-CIK cells combined with chemotherapy is safe and effective for advanced NSCLC, and it can also improve the remission rate, survival and quality of life of NSCLC patients.
Keywords:
Project Supported:
Project supported by the Key Scientific Foundation of Science and Technology Bureau of Shanxi Province (No.051096-2)
Clc Number:
